18:56 , Dec 13, 2018 |  BC Innovations  |  Translation in Brief

3-D immune response

A Boston Children's Hospital team has developed a 3-D human tissue model that reproduces age-specific immune responses to vaccine antigens and could surmount the hurdles of developing vaccines for neonates and infants. Preclinical vaccine development...
17:51 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

New BCMA-targeted therapies could help sicker patients

Oral abstracts at this year’s American Society of Hematology meeting describing next generation anti-BCMA CARs from Poseida Therapeutics Inc. and Fred Hutchinson Cancer Research Center and a bispecific antibody from Amgen Inc. (NASDAQ:AMGN) hint that...
17:31 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Celgene reports updated ORR of 82% for anti-BCMA CAR T therapy in MM

The Juno Therapeutics Inc. subsidiary of Celgene Corp. (NASDAQ:CELG) reported updated data from the Phase I/II EVOLVE trial to treat relapsed and/or refractory multiple myeloma in patients who have received at least three prior regimens...
01:23 , Dec 7, 2018 |  BC Week In Review  |  Financial News

Panacea backs Tactiva in $35M series A

Cancer immunotherapy company Tactiva Therapeutics Inc. (Buffalo, N.Y.) announced Dec. 3 it raised $18 million in the first tranche of a $35 million series A round led by Chinese VC firm Panacea Ventures. VI Ventures...
23:00 , Dec 4, 2018 |  BC Extra  |  Clinical News

New BCMA-targeted therapies could help sicker patients

Oral abstracts at this year’s American Society of Hematology meeting describing next generation anti-BCMA CARs from Poseida Therapeutics Inc. and Fred Hutchinson Cancer Research Center and a bispecific antibody from Amgen Inc. (NASDAQ:AMGN) hint that...
22:49 , Dec 3, 2018 |  BC Extra  |  Financial News

Panacea backs Tactiva in $35M series A

Cancer immunotherapy company Tactiva Therapeutics Inc. (Buffalo, N.Y.) announced Monday it raised $35 million in a tranched series A round led by Chinese VC firm Panacea Ventures. VI Ventures and EFung Capital also participated. Tactiva...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
03:21 , Nov 17, 2018 |  BioCentury  |  Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
17:38 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

ViiV's fostemsavir maintains virologic suppression at week 48 in Phase III for HIV

ViiV Healthcare Ltd. (Brentford, U.K.) said fostemsavir plus optimized background therapy maintained virologic suppression of less than 40 copies/mL from week 24 to 48 in 54% of heavily treatment-experienced patients with HIV-1 infection in the...
19:51 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

BCMA race heats up as ASH abstracts released

Abstracts released ahead of next month's American Society of Hematology meeting highlighted the competition among products representing three anti-BCMA (TNF receptor superfamily member 17; TNFRSF17; CD269) modalities in development to treat multiple myeloma. On the...